Prevalence of overweight and obesity in European children below the age of 10

W Ahrens1, I Pigeot1, H Pohlabeln2

  • 11] Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany [2] Faculty of Mathematics and Computer Science, Institute of Statistics, Bremen University, Bremen, Germany.

Insights

European children face significant overweight and obesity disparities, with higher rates in southern regions and lower socioeconomic groups. Addressing these inequalities requires reinforced public health policies to prevent childhood obesity.

Area of Science:

  • Pediatric Public Health
  • Nutritional Epidemiology
  • Childhood Obesity Research

Background:

  • Lack of standardized surveillance for childhood overweight and obesity across Europe.
  • Existing data comparability is limited by sampling, methods, and quality assurance.
  • The IDEFICS study offers a large, methodologically robust European dataset on young children's health.

Purpose of the Study:

  • To analyze the European distribution of weight status in children aged 2.0-9.9 years using various BMI classification systems.
  • To determine the prevalence of weight categories by region, sex, age, and socioeconomic position.
  • To highlight regional and socioeconomic disparities in childhood overweight and obesity.

Main Methods:

  • Utilized data from 18,745 children across eight European countries (2007-2010).
  • Employed a highly standardized protocol including anthropometric measurements and parental socio-demographic reports.
  • Applied different reference systems for Body Mass Index (BMI) classification.

Main Results:

  • Combined overweight/obesity prevalence varied widely, from <10% in Northern Europe to >40% in Southern Europe.
  • Overweight prevalence was higher in girls (21.1%) than boys (18.6%).
  • Obesity prevalence negatively correlated with socioeconomic position, being highest in low-income/education groups.

Conclusions:

  • Southern European populations and those with lower socioeconomic status exhibit higher obesity rates.
  • Significant regional and socioeconomic disparities in childhood obesity necessitate action.
  • Reinforced European public health policies are crucial for preventing early obesity and reducing health inequalities.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
352
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
2.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373